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The physiological structure of human C-reactive protein and its
complex with phosphocholine
Darren Thompson1, Mark B Pepys2 and Steve P Wood1*
Background: Human C-reactive protein (CRP) is the classical acute phase
reactant, the circulating concentration of which rises rapidly and extensively in a
cytokine-mediated response to tissue injury, infection and inflammation. Serum
CRP values are routinely measured, empirically, to detect and monitor many
human diseases. However, CRP is likely to have important host defence,
scavenging and metabolic functions through its capacity for calcium-dependent
binding to exogenous and autologous molecules containing phosphocholine
(PC) and then activating the classical complement pathway. CRP may also
have pathogenic effects and the recent discovery of a prognostic association
between increased CRP production and coronary atherothrombotic events is of
particular interest.
Results: The X-ray structures of fully calcified C-reactive protein, in the presence
and absence of bound PC, reveal that although the subunit β-sheet jellyroll fold is
very similar to that of the homologous pentameric protein serum amyloid P
component, each subunit is tipped towards the fivefold axis. PC is bound in a
shallow surface pocket on each subunit, interacting with the two protein-bound
calcium ions via the phosphate group and with Glu81 via the choline moiety.
There is also an unexpected hydrophobic pocket adjacent to the ligand.
Conclusions: The structure shows how large ligands containing PC may be
bound by CRP via a phosphate oxygen that projects away from the surface of
the protein. Multipoint attachment of one planar face of the CRP molecule to a
PC-bearing surface would leave available, on the opposite exposed face, the
recognition sites for C1q, which have been identified by mutagenesis. This
would enable CRP to target physiologically and/or pathologically significant
complement activation. The hydrophobic pocket adjacent to bound PC invites
the design of inhibitors of CRP binding that may have therapeutic relevance to
the possible role of CRP in atherothrombotic events.
Introduction
C-reactive protein (CRP) is a normal plasma protein, the
circulating concentration of which rises dramatically in a
cytokine-mediated response to most forms of tissue injury,
infection and inflammation, and serum CRP values are
widely measured in clinical practice as an objective index
of disease activity [1,2]. CRP is a member of the evolu-
tionarily ancient and stably conserved pentraxin family
that includes serum amyloid P component (SAP) [3], an
important constituent of the amyloid deposits that under-
lie a range of human diseases including Alzheimer’s [4,5].
The conservation of the structure of CRP and of its
calcium-dependent specific binding of ligands containing
phosphocholine (PC) [6] and related substances, together
with the failure thus far to detect any polymorphism or
deficiency of CRP in man, argue strongly that CRP has
an important physiological role. PC is universal in phos-
pholipids in cell membranes and plasma lipoproteins,
and is common in complex polysaccharides of plants,
fungi and bacteria, whilst CRP also binds specifically to
small nuclear ribonucleoprotein particles [7,8]. Ligand
recognition and binding by CRP may thus contribute to a
range of metabolic, scavenging and host-defence func-
tions. The recent discovery of a significant prognostic
association between increased levels of serum CRP and
coronary heart disease, especially myocardial infarction,
has greatly heightened interest in this classical acute
phase reactant, but, importantly, the association with coro-
nary disease is evident even at CRP levels previously con-
sidered normal [9–15].
The capacity of human CRP to activate complement
[16–20] and to stimulate tissue-factor production [21–23]
suggests that CRP may have pro-inflammatory and proco-
agulant effects, and we have proposed [9,13] that these
may contribute to pathogenesis of the progression and
thrombo-occlusive complications of atheroma. CRP may
thus be a significant therapeutic target and its molecular
structure–function relationships are therefore potentially
of practical as well as theoretical importance.
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Although CRP was originally crystallised in 1947 [24],
forms suitable for high-resolution X-ray analysis have not
previously been obtained [25]. The 3 Å resolution struc-
ture of partially calcium-loaded (one protomer in each
pentamer contained no bound calcium) CRP (Brookhaven
Protein Data Bank [PDB] code 1gnh) was published during
the course of the present work [26], but it was based on
incomplete data with poor processing statistics collected




The crystal structure of CRP was determined by molecu-
lar replacement, using human serum amyloid P component
as the search model [27], but with the two calcium ions per
subunit deleted. The asymmetric unit of the CRP crystal,
grown in the presence of excess calcium, contained two
pentamers that allowed tenfold averaging to produce a good
quality electron-density map that enabled model building.
The final R factor of this structure was 18.6% (R free 23%)
to a resolution of 3 Å.
The structure of CRP co-crystallised with PC and calcium
was determined from a crystal form containing only one
pentamer in the asymmetric unit. Again, molecular replace-
ment was used, but this time the CRP structure deter-
mined from the previous crystal form was used as the search
model. Although the cell dimensions from each of these
crystal forms are very similar, they are in fact of different
space groups with very different solvent volumes (ligand
free 53%, PC-bound 76%) and this is why the molecular
replacement was needed to solve the PC-bound structure.
Initial electron-density maps produced showed density for
one molecule of PC in each subunit, bound at the double
calcium binding site. The final R factor of this structure was
19.6% (R free 24.2%) to a resolution of 2.5 Å. On final
comparison of the two structures, we found that the packing
of the unliganded structure with two molecules in the
asymmetric unit was such that it would be very difficult to
accommodate PC molecules bound to each subunit. Other-
wise, the two structures are extremely similar (a root mean
square [rms] difference of 0.29 Å), with only minor changes
in the positions of sidechains involved in ligand binding and
crystal contacts. For this reason, the following analysis of
the structure of CRP applies to both structures.
The structure of the CRP protomer
As we predicted [28] from homology modelling based on
the crystal structure of SAP, the CRP protomer is very
similar to that of SAP; the Cα rms fit is 1.3 Å, but it drops
to 0.83 Å when three divergent loops involving 19 residues
are omitted from the calculation (Figure 1). The subunits
consist of a two-layered β sheet with a flattened jellyroll
topology. Two calcium ions are bound 4 Å apart by protein
sidechains coming from loops collected at the concave face,
designated B [29], of this sheet, and this is the site of
ligand binding. The other face, designated A, carries a single
α helix, and the pentameric disc shows five helices on one
face and ten calcium ions on the other. The main structural
differences in CRP occur in the longer β arches and loops
linking top and bottom strands adjacent to the central
pore of the pentamer (residues 43–48, 68–72, 85–91). Short
helical regions form around residues 43 and 185.
On the A face of each subunit, there is a marked furrow
(Figure 2a) that is accentuated in CRP by substitution of
some smaller sidechains and by reorientation of others, and
it defines a region 24 Å long, 7.5 Å deep and 12.4 Å wide.
The side walls are constructed from Ser5, Arg6, Gln203,
Pro206, Trp187, Arg188, Asn160, Gly177, Leu176, Tyr175,
His95 and Asp112. The bottom is lined by Asn158, His38,
Leu37, Val94 and Asp112. The appearance of this furrow
in CRP is enhanced considerably by differences in the
pentamer organisation compared to SAP. The furrows
follow the curvature of the subunits and come closer
together as they enter the pore at the centre of the pen-
tamer. The outer part of the furrow is positively charged
but the inner part terminates halfway through the pentamer
pore at residue Asp112, providing a ring of negative charges
lining the pore (Figure 2b). Mutagenesis experiments have
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Figure 1
Ribbon overlay of an SAP protomer (yellow) and a CRP protomer
(green) after a 22o rotation has been applied to the SAP protomer so
as to bring the protomers into the same orientation. The red coloured
CRP loops comprise residues 43–48, 68–72 and 85–91, which are
the regions differing most between the two protomer structures.
Structure
highlighted Asp112 as an important residue for recogni-
tion of C1q by CRP [30].
The structure of the CRP pentamer
In SAP, the core β sheets of each protomer are in a plane
approximately normal to the fivefold axis. In contrast, each
subunit in CRP for both crystal forms is rotated by 22°
towards the fivefold axis (Figure 3) such that the helices of
face A are 5 Å closer to the axis and the calcium sites on face
B move away by an equivalent amount. The rotational shift
of 22° observed between the orientations of SAP and CRP
protomers was calculated by first superimposing the pen-
tamers from both molecules such that the fivefold axes of
the two proteins were parallel and equivalent protomers
were superimposed. The equivalent protomers of CRP and
SAP were then compared using LSQKAB (CCP4 suite) [31]
to determine the rotational relationship between the two in
polar angles. The rotation axis is roughly parallel to the long
helix on the surface of the protomer and runs through the
centre of mass of the subunit.
The interactions between subunits in the SAP pentamer
involve van der Waals contacts and hydrogen bonding, and
lead to 1650 Å2 (20%) of buried surface per protomer. The
contacts involve the open-core end of the β-sheet sandwich
of one subunit with the N- and C-terminal strands of the
next. A rather similar surface area is buried in CRP, but
changes in sequence relative to SAP and the subunit rota-
tion lead to small changes in the bonding pattern that must
stabilise the rotated state of the subunits. For instance,
residues Glu197 and Lys123 in CRP form an intermolecu-
lar ion pair not formed by Tyr195 and Gln121 in SAP.
The CRP Asp155–Arg118 and Glu101–Lys201 ion pairs,
however, correspond to Glu153–Lys116 and Glu99–Lys199
in SAP. When we impose the observed subunit rotation of
CRP onto the SAP coordinates, there are surprisingly few
major clashes, the most notable being between Val202 and
Pro166 of the adjacent subunit. In CRP, the equivalent
Leu204 moves to a new position and the mainchain path
increasingly deviates from the equivalent region in rotated
SAP beyond Pro202, away from the subunit interface. This
leads to a marked reorganisation of the position of the
Trp205 ring in CRP, compared to SAP Trp203 (Figure 4),
resulting from a mainchain shift and a rotation of about 90°
around the Cβ–Cγ bond, so that the ring stacks at a dis-
tance of 3.7 Å with the sidechain of His38 (corresponding
to SAP Arg38) of the same subunit. In view of the modest
surface area buried and the relative ease of interconverting
the subunit packing arrangements it is possible that such
movements represent a dynamic capacity of both mole-
cules. Crystal packing forces may play a role in stabilising
a particular arrangement and in all our crystal forms there
are substantial face to face contacts between adjacent pen-
tamers. Interestingly, such movements of the protomers
redistribute the ligand-binding sites on the B face of the
pentamer and might be of significance in multivalent
binding to structures such as cell membranes, protein aggre-
gates, or nucleic acid–protein complexes.
The calcium-binding site
The calcium-binding sites in the present CRP structures
are organised in a similar fashion to those in SAP, but a
number of differences in the protein ligands to the calcium
ions help to explain known differences in the calcium affin-
ity between the proteins. In SAP, there is distinct asym-
metry in the ligand distribution such that site 1 calcium
receives six protein ligands whereas site 2 calcium receives
only three. In both sites, carboxylate or phosphate ligands
provide one additional bond per metal atom. The larger
site 2 pocket can accommodate a barium or cerium ion.
Calcium ions wash out rather easily and the site is only
partially occupied in the SAP crystal structure; it may
exist in a partially calcium loaded form at physiological
calcium concentrations in the absence of external ligands.
The equivalent site 1 residues in CRP include Asp60,
Asn61, Glu138, Asp140 and the mainchain carbonyl oxygen
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Figure 2
GRASP representation of (a) CRP pentamer
illustrating the positions of the clefts present
on the A surface; (b) CRP protomer
illustrating the charge distribution in the cleft.
Blue, positive charge; red, negative.
of residue 139, but Asp60 provides only one oxygen
ligand to the calcium ion (total of five ligands). The equiv-
alent site 2 residues include Gln138, Asp140 and Gln150.
Residue Glu147 (Asp145 in SAP) extends sufficiently to
close the pocket with an additional bond to calcium (four
ligands total), although in the 1gnh structure of CRP the
sidechain of Glu147 is not positioned to coordinate the
calcium ion. Thus, in CRP, the two calcium-binding sites,
which are of equal affinity in solution [32], are differenti-
ated by one carbonyl oxygen ligand and are equally occu-
pied in the crystal. When both calcium sites are vacant in
CRP, residues 140–150 form a large loop away from the
body of the molecule [26], exposing an otherwise hidden
site of proteolysis. In SAP, site 2 loses calcium most readily,
but subunits containing a single calcium have an unchanged
structure (unpublished results), indicating that site 1 inter-
actions through Asp140 are required to stabilise the folded
state of this loop.
The phosphocholine-binding site
Initial difference maps calculated from reflection data
sets collected from the crystals grown in the presence of
PC showed very good density for one molecule of PC in
each of the five subunits of CRP (Figure 5a) [33]. The
major interaction between CRP and PC occurs between
the phosphate group of PC and the bound calciums. Two
of the oxygens interact directly with each calcium, leaving
the third oxygen pointing away from the binding site and
into the solvent. This orientation would allow CRP to bind
PC when the phosphate moiety is in ester linkage with
other molecules. The remaining part of the PC molecule
extends from this site and runs along the surface of CRP,
packed against Phe66, towards the sidechain of residue
Glu81 (Figure 5b). The distance between the positively
charged quaternary nitrogen of PC and the acidic side-
chain of Glu81 is 3.8 Å, suggesting that this interaction is
an important determinant of PC binding. In SAP, the
equivalent residue, the positively charged Lys79, would
not favour this arrangement. Furthermore, Tyr74 of SAP
would clash with the trimethyl ammonium group of PC.
In CRP, this residue is Thr76, the small sidechain of which
leaves a hydrophobic cavity (8.7 × 7 × 3.5 Å3) on the surface
of CRP lined by atoms from Glu81, Gly79, Asn61 and
Thr76 (Figure 6). The existence of this pocket encour-
ages design of branched PC analogues with bulky sub-
stituents at the 2 position that could be bound with higher
affinity than PC. These would be powerful reagents to
investigate CRP function as well as having the potential
as drugs to block possible harmful effects of CRP in vivo.
These results are in general agreement with earlier mole-
cular modelling studies [28].
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Figure 3
Ribbon overlay of an SAP protomer (yellow) and a CRP protomer
(green) indicating the orientation of the protomers with respect to the
fivefold axis of the pentamers.
Figure 4
An overlay of SAP residue Trp203 (blue) and CRP residue Trp205
(green), indicating the reorganisation of the two residues.
Comparison of human CRP and other pentraxins
The CRP structure complexed with PC showed the major
interactions to occur between two phosphate oxygens and
the calciums and the positively charged quaternary nitrogen
of PC and the negatively charged sidechain of Glu81. This
residue is Lys79 in SAP and would therefore not favour
this arrangement. Furthermore, Tyr74 of SAP would clash
with the trimethyl ammonium group of PC. This is Thr76
in CRP. This explains the failure of SAP to bind PC with
high affinity. When the structure of CRP complexed with
PC is superimposed onto a structure of SAP complexed
with phosphoethanolamine, the phosphoethanolamine mol-
ecule is shown to interact with the calcium ions in the
same way as PC, but then the remaining part of the mole-
cule follows a different direction and heads towards Glu66
(Ser68 in CRP). The nitrogen end of PE is held in place by
this residue via a water molecule that is bound between the
nitrogen and Glu66. The SAP from female hamster is able
to bind both amyloid and PC, thus combining the specifici-
ties of human SAP and CRP [34]; however, Tyr74, which
would obstruct PC binding by SAP, is retained in hamster
whereas Glu81 is replaced by Gly. Glu66 present in human
SAP is retained in hamster SAP and may act as the point of
interaction for the quaternary nitrogen of PC. Due to the
substitution of Lys79 in human SAP with Gly in hamster
SAP, there is space and flexibility in the mainchain to allow
repositioning of Tyr74 to remove the steric limitation on PC
binding, and Tyr74 may be positioned in an orientation that
allows van der Waals contacts with PC, guiding the mole-
cule towards Glu66.
Another difference in ligand specificity between SAP and
CRP is the ability of SAP to bind the cyclic acetal of galac-
tose, methyl 4,6-O-(1-carboxyethylidene)-β-D-galactopyra-
noside (MOβDG). There are only two significant differences
between the proteins in the region of SAP at which
MOβDG is bound. The interaction between the sidechain
of SAP Lys79 and MOβDG cannot be satisfied by CRP
Glu81, and van der Waals contacts to MOβDG provided by
SAP Trp74 are not available from CRP Thr76. The pres-
ence of these different residues is therefore likely to be
responsible for the failure of CRP to bind MOβDG.
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Figure 5
The binding of phosphocholine to C-reactive
protein. (a) Difference Fourier map at 2.5 Å
resolution, contoured at 2σ, showing the
positions of the two calcium ions (orange) and
a molecule of phosphocholine. (b) GRASP
representation of CRP illustrating the
positions of the five bound molecules of
phosphocholine (orange and black).
Figure 6
GRASP representation of the phosphocholine-binding site showing
the vacant pocket adjacent to the ligand.
There are several small differences between the structure
described here and that published by Shrive et al. (PDB
code – 1gnh) [26], which includes sidechains where the
electron density is expected to be less well defined, for
example, Arg58, Lys31, Lys114 and Arg116. In the case of
Arg116, this leads to the removal of an intersubunit ion
pair with Glu42 of an adjacent protomer present in 1gnh
and its replacement by a hydrogen bond to the mainchain
of residue Glu85 of the same subunit in this work. In areas
of stronger electron density, we find that Phe180 differs in
orientation by a rotation of 180° about the Cα–Cβ bond
compared to 1gnh. The protomers of this structure (1 gnh)
that had calcium bound had an rms difference of 0.36 Å
compared to the CRP structure described here. However,
this figure increased to 1.74 Å when the 1gnh protomers
without calcium were compared to the protomers described
in this paper. The extent of subunit rotations are similar in
all of the structures.
A model for CRP-mediated binding of C1q to the cell surface
The micromolar affinities of the pentraxin subunits for their
respective small molecule univalent ligands are modest.
The presence of multiple equivalent binding sites on a
pentamer can, however, facilitate formation of rather stable
complexes, as seen in the BB face-to-face decamers of
SAP produced through base stacking of bound dAMP mol-
ecules [35]. It is not currently known to what extent the
pentameric array of binding sites may contribute to amyloid
recognition for SAP, but multisite interactions can be
readily visualised in the binding of CRP to phospholipid
PC headgroups in cell membranes.
Cells undergoing apoptosis and even nonirremediably
damaged cells show flip-flop exchange between the inner
and outer leaflets of the lipid bilayer, which is permissive
for phospholipase action in producing lysolipids. CRP binds
only to damaged plasma membranes, in which there is an
increased proportion of lysophospholipid, and can then
activate complement, presumably to promote beneficial and
scavenging functions, but also possibly to enhance tissue
injury [36–39]. The elements of CRP–ligand recognition
discussed here can be assembled into a working hypothe-
sis of the mode of targeting complement attack to compro-
mised cells and this is presented in cartoon form in Figure 7.
Similar considerations may apply to the binding of CRP
and its scavenging and immunosuppressive functions [40]
with regard to small nuclear ribonucleoprotein particles,
the unique nuclear constituent to which CRP specifically
binds under physiological extracellular ionic strength condi-
tions [7,8]. SAP is the main chromatin and DNA-binding
protein of the plasma [41], and the recent discovery in
SAP knockout mice that one of its major functions is to
prevent anti-chromatin autoimmunity [42] refocuses atten-
tion on the well-known defect in CRP response to the
inflammatory pathology of human systemic lupus erythe-
matosus [43]. Small nuclear ribonucleoprotein particles
are strong candidate autoantigens for the induction of auto-
antibodies cross-reactive with double-stranded DNA [44],
and the mode of binding of CRP and its effects are there-
fore of considerable interest with respect to the handling
of these autoantigens and the pathogenesis of antinuclear
autoimmune disease.
Investigation of these CRP functions is in progress through
the structural analysis of additional CRP–ligand complexes,
coupled with protein engineering studies to define ligand-
binding mechanisms and facilitate drug design.
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Figure 7
CRP (black pentagons) binds via the B face calcium sites to PC head
groups of phospholipids on membranes perturbed by the action of
phospholipase to produce lysolipids (black), the stability of the
complex being determined by the cooperative fivefold repetition of the
interaction and the high two-dimensional (2D) concentration of ligands.
CRP molecules are known from electron microscopy to form ordered
2D arrays at surfaces and this effect is likely to occur on the lipid
bilayer, as has been shown for Annexin V [50]. A number of proteins,
including phospholipase Cβ, phospholipase A2, rabphilin 3A and
synaptotagmin I, interact with cell membranes in a calcium-dependent
manner via their Greek-key C2 domains [51–54]. Adjacent bound
CRP molecules may present multiple binding sites via the A face
furrows and central pore region for the head groups of C1q arms,
providing a mechanism for head group cross-linking that is known to
be involved in Fc activation of C1q by immune complexes and an
explanation for the observed requirement that CRP be aggregated to
the level of dimers or trimers for in vitro activation of complement.
Highly basic peptides from the C1q A chain (76–92 and 14–26) are
involved in the interaction [20]. Aggregated SAP also activates
complement, but in the context of the above model we know that the B
face ligand specificity is different, the spatial disposition of the binding
sites is different, the architecture of the A face is modified and the pore
is lined by five lysines (K87) at similar positions to the Asp112 of CRP,
suggesting that these activation reactions are expressed in quite
distinct biological contexts. The long pentraxin PTX3 also binds C1q
via its pentraxin homology domain when in its native oligomeric state
but the protein does not share the calcium and other ligand binding
properties of SAP and CRP [55]. Residues H95 and W187 are the







C-reactive protein (CRP), named for its binding to pneu-
mococcal somatic C-polysaccharide, is the classical acute
phase protein, the concentration of which increases in
response to tissue injury, infection and inflammation.
Serum CRP assays are universally used to monitor
disease activity and response to therapy. CRP belongs to
the highly conserved pentraxin protein family and con-
tributes to innate immunity against infection and to han-
dling of autologous ligands, probably helping to prevent
development of autoimmunity. The autologous ligands of
CRP include phospholipids and ribonucleoproteins from
necrotic and apoptotic cells. CRP binds phosphocholine
with the highest affinity and we describe here for the first
time the precise molecular mechanism of this interaction.
Complexed or aggregated CRP activates complement,
with pro-inflammatory effects, and recent observations
have focused attention on a possible pathogenetic role of
CRP. Firstly, it has been discovered that increased
levels of CRP strongly predict the thrombo-occlusive
complications of atherosclerosis, especially myocardial
infarction. Secondly, CRP levels after myocardial infarc-
tion can  predict complications and outcome, including
death. CRP itself is deposited in the infarcted tissue and
it activates complement. This presumably promotes ben-
eficial and scavenging functions, but it also enhances
tissue injury. Inhibition of this effect of CRP is thus an
attractive therapeutic target.
On the basis of the elements of phosphocholine ligand
recognition by CRP reported here, we suggest a possible
mode of targeting complement activation to compromised
cells. Similar considerations may apply to the binding of
CRP to its bacterial ligands and to the autologous cellu-
lar components that are the putative foci of its scavenging
and immunosuppressive functions. Furthermore, the
present structural solution will assist development and
refinement of inhibitors of CRP binding for use as drugs.
Materials and methods
Crystallisation
Human CRP was prepared as described previously [37]. Bi-pyramid
crystals, approximately 1 × 0.4 × 0.4 mm for both forms, were grown by
the hanging-drop vapour-diffusion method. The drop, made up of a 1:1
ratio of CRP (40 mg/ml):well solution, was equilibrated against a well solu-
tion of 60 mM HEPES buffer (pH 7.6), 140 mM NaCl, 10 mM calcium
acetate and 10% v/v MPD. In the absence of ligand, the crystal was of
space group P43212 with cell dimensions a = b = 190.31, c = 132.12 Å.
Crystals of similar morphology were grown under the same conditions
as above but in the presence of 100 mM PC. These were of similar cell
dimensions to those described above: a = b = 193.94, c = 134.43 Å,
but were in space group P41212 (Crystal form II). In both cases, the
selection of the enantiomorph was based on strong and unequivocal
translation function peaks.
Data collection and processing
Data were collected from the first crystal form using a 300 mm Mar
image plate mounted on a rotating anode. These crystals diffracted to a
resolution of 3.0 Å. Data were collected from the second crystal form at
CLRC Daresbury PX 9.6, λ = 0.89 Å with a 300 mm Mar image plate.
This crystal was frozen in a stream of cold nitrogen gas at 100ºK (Oxford
Cryostreams) and diffracted to a resolution of 2.5 Å. In each case, 90
images were collected, each covering 1° of rotation. Both data sets were
processed with the program MOSFLM [45] and programs from the
CCP4 suite. A summary of the data statistics is shown in Table 1.
Obtaining the phases with molecular replacement (Form I)
X-PLOR [46] was initially used to calculate the cross rotation function,
with a pentamer of SAP being used as the search model. This was fol-
lowed by Patterson correlation refinement. This failed to produce a signif-
icant peak, as did the program Amore [47]; however, when Patterson
correlation refinement [46] was performed on the solutions obtained from
Amore, a significant solution was observed that allowed translation para-
meters to be calculated. This peak was nineteenth in the list originally
output from Amore. X-PLOR was used to calculate the translation func-
tion and produced a peak 16 sigma above the mean. This peak was only
observed after the Patterson correlation refinement was performed on
the rotation solution, which had the effect of rotating the protomers of
SAP into positions similar to that of CRP. The orientation of the second
pentamer was estimated from a self rotation function map and its transla-
tion parameters determined using a reoriented copy of the first pentamer.
Obtaining the phases with molecular replacement (Form II)
Crystal form II was readily solved by molecular replacement using the
form I structure as the search model and the translation function to
establish the enantiomorph. For both structures, the appearance in initial
electron density maps of two calcium atoms that had been excluded
from the search model provided support for the solution.
Model building and refinement
The model was rebuilt from the SAP coordinates using the program O
[48] and averaged maps calculated using programs from the CCP4
suit. Refinement was carried out with data to the highest resolution
available. X-PLOR was used in both instances. The final R factor for the
CRP–calcium structure was 18.6% and the final R-factor for the CRP–
calcium–PC structure was 19.6%. The program PROCHECK [49] was
used to analyse the stereochemistry of the models and showed no
residues in the disallowed regions of a Ramachandran plot. A summary
of the refinement statistics is shown in Table 1.





Data resolution 3 Å 2.5 Å
Completeness (%) 94.6 97.6
Highest shell (%) 92 94.5
Multiplicity 3.6 4.3
I/σI 8.9 10.1
Rmerge (%) 6.3 6.8
Rref (%) 18.6 19.6
free (%) 23 24.2
Space group P43212 P41212
Cell (Å) A = B = 190.31 A = B = 193.94
C = 132.12 C = 134.43
Number. of reflections 46,391 86,545
Rms bond lengths (Å) 0.012 0.01
Rms bond angles (o) 1.7 1.5
Accession numbers
The atomic model coordinates for the structure described in this paper
have been deposited with the Brookhaven Protein Data bank with acces-
sion code 1b09.
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